Reasonableness analysis and efficacy evaluation of thymalfasin for viral pneumonia based on real-world data
Objective Based on real-world data,to analyze the use condition of thymalfasin injection in a hospital,and to explore its rationality in the prevention and treatment of viral pneumonia,in order to provide reference for the clinical rational use of thymic peptide drugs.Methods A retrospective study method was used to collect cases of thymalfasin used in a hospital from December 2022 to March 2023 for a full sample review.The rationality was evaluated from the aspects of medication indications,timing,dosage and course of treatment,the prognosis was followed up,the efficacy was evaluated.Results A total of 174 patients were included,80.46%of them were older than 65 years old,and most of them were hospitalized for 7～14 days.Respiratory department and ICU patients accounted for the largest proportion,mainly diagnosed as COVID-19 infec-tion,severe pneumonia,sepsis,etc.Most cases were complicated with multiple diseases,after comments,the unreasonable rate of indications for thymalfasin injection was 24.14%;the proportion of unsuitable dosage was 12.10%,the proportion of unsuitable route of administration was 2.63%,and the proportion of unsuitable solvent was 12.89%.Conclusion Real-world data suggests that there is an unreasonable use of thymalfasin,which has certain therapeutic effects on COVID-19 critically ill patients with weakened immunity.It is recommended that COVID-19 patients strictly grasp the indications and timing of thymalfasin use,and use medication with caution.
NETL
NSTL
万方数据
